Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT04351763

Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms (ReCOVery-SIRIO)

Sponsor: Nicolaus Copernicus University

Conditions COVID-19

Updated 5 times since 2020 Last updated: Aug 30, 2021 Started: May 20, 2020 Primary completion: May 25, 2021 Completion: Jun 5, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04351763, this PHASE2/PHASE3 trial focuses on COVID-19 and remains completed. Sponsored by Nicolaus Copernicus University, it has been updated 5 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Oct 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2_PHASE3
May 2020 — Jan 2021 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nicolaus Copernicus University

Data source: Nicolaus Copernicus University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bydgoszcz, Poland